Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 5
2004 3
2005 4
2006 7
2007 3
2008 3
2010 3
2011 6
2012 5
2013 7
2014 3
2015 5
2016 4
2017 3
2018 5
2019 5
2020 9
2021 9
2022 9
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies.
Viviani S, Vanazzi A, Frassoni S, Rusconi C, Rossi A, Romano A, Patti C, Schiavotto C, Sorasio R, Marasco V, Lissandrini L, Rapezzi D, Gottardi D, Cocito F, Mulè A, Leotta S, Gini G, Sorio M, Derenzini E, Rambaldi A, Bagnardi V, Tarella C. Viviani S, et al. Among authors: tarella c. Leuk Lymphoma. 2024 Apr;65(4):460-471. doi: 10.1080/10428194.2023.2298273. Epub 2024 Jan 2. Leuk Lymphoma. 2024. PMID: 38164812
[18 F]-FDG PET radiomic model as prognostic biomarker in diffuse large B-cell lymphoma.
Travaini LL, Botta F, Derenzini E, Lo Presti G, Ferrari ME, Airò Farulla LS, Radice T, Mazzara S, Tarella C, Pileri S, Raimondi S, Ceci F. Travaini LL, et al. Among authors: tarella c. Hematol Oncol. 2023 Oct;41(4):674-682. doi: 10.1002/hon.3171. Epub 2023 May 20. Hematol Oncol. 2023. PMID: 37209024 Free article.
Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL.
Mazzara S, Travaini L, Botta F, Granata C, Motta G, Melle F, Fiori S, Tabanelli V, Vanazzi A, Ramadan S, Radice T, Raimondi S, Lo Presti G, Ferrari ME, Jereczek-Fossa BA, Tarella C, Ceci F, Pileri S, Derenzini E. Mazzara S, et al. Among authors: tarella c. Blood Adv. 2023 Feb 28;7(4):630-643. doi: 10.1182/bloodadvances.2022007825. Blood Adv. 2023. PMID: 36806558 Free PMC article.
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.
Todisco E, Papayannidis C, Fracchiolla N, Petracci E, Zingaretti C, Vetro C, Martelli MP, Zappasodi P, Di Renzo N, Gallo S, Audisio E, Griguolo D, Cerchione C, Selleri C, Mattei D, Bernardi M, Fumagalli M, Rizzuto G, Facchini L, Basilico CM, Manfra I, Borlenghi E, Cairoli R, Salutari P, Gottardi M, Molteni A, Martini V, Lunghi M, Fianchi L, Cilloni D, Lanza F, Abruzzese E, Cascavilla N, Rivellini F, Ferrara F, Maurillo L, Nanni J, Romano A, Cardinali V, Gigli F, Roncoroni E, Federico V, Marconi G, Volpi R, Sciumè M, Tarella C, Rossi G, Martinelli G; AVALON Cooperative Group. Todisco E, et al. Among authors: tarella c. Cancer. 2023 Apr 1;129(7):992-1004. doi: 10.1002/cncr.34608. Epub 2023 Jan 24. Cancer. 2023. PMID: 36692409 Free article.
The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade.
Tabanelli V, Melle F, Motta G, Mazzara S, Fabbri M, Agostinelli C, Calleri A, Del Corvo M, Fiori S, Lorenzini D, Cesano A, Chiappella A, Vitolo U, Derenzini E, Griffin GK, Rodig SJ, Vanazzi A, Sabattini E, Tarella C, Sapienza MR, Pileri SA. Tabanelli V, et al. Among authors: tarella c. Blood Adv. 2022 Aug 9;6(15):4634-4644. doi: 10.1182/bloodadvances.2022007046. Blood Adv. 2022. PMID: 35767735 Free PMC article.
Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes.
Todisco E, Gigli F, Ronchini C, Amato V, Sammassimo S, Pastano R, Parma G, Lapresa MT, Bertolini F, Corsini C, Gregato G, Poletti C, Pelicci PG, Alcalay M, Colombo N, Tarella C. Todisco E, et al. Among authors: tarella c. Int J Cancer. 2022 Nov 15;151(10):1791-1803. doi: 10.1002/ijc.34162. Epub 2022 Jul 2. Int J Cancer. 2022. PMID: 35695283 Free PMC article.
The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19.
Cristiano A, Palmieri R, Fabiani E, Ottone T, Divona M, Savi A, Buccisano F, Maurillo L, Tarella C, Arcese W, Voso MT. Cristiano A, et al. Among authors: tarella c. Mediterr J Hematol Infect Dis. 2022 May 1;14(1):e2022041. doi: 10.4084/MJHID.2022.041. eCollection 2022. Mediterr J Hematol Infect Dis. 2022. PMID: 35615323 Free PMC article.
Advances in therapeutic strategies for primary CNS B-cell lymphomas.
Ramadan S, Radice T, Ismail A, Fiori S, Tarella C. Ramadan S, et al. Among authors: tarella c. Expert Rev Hematol. 2022 Apr;15(4):295-304. doi: 10.1080/17474086.2022.2061455. Epub 2022 Apr 25. Expert Rev Hematol. 2022. PMID: 35467473 Review.
91 results